New hope for tough myasthenia gravis cases? eculizumab trial in china
NCT ID NCT06764160
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 3 study tested eculizumab in 15 Chinese patients with refractory generalized myasthenia gravis (gMG), a condition where standard treatments fail. Eculizumab is given by IV infusion and aims to improve daily living activities and muscle strength. The study measured changes in symptom scores over 26 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
eculizumab
What this could lead to
If successful, this could provide a new treatment option for Chinese patients with hard-to-control generalized myasthenia gravis.
What could go wrong
This is a small, single-arm study with only 15 participants, so results may not apply broadly. Eculizumab can increase risk of serious infections, including meningitis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS (GMG) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Changchun, 130021, China
-
Research Site
Fuzhou, 350001, China
-
Research Site
Guangzhou, 510080, China
-
Research Site
Guangzhou, 510620, China
-
Research Site
Qingdao, 266035, China
-
Research Site
Shanghai, 200040, China